Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSC for COVID-19 ARDS
NCT04390152Phase 2Terminated
- Sponsor
- BioXcellerator
- Start
- Jan 2020
- Primary completion
- Mar 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Wharton's jelly-derived mesenchymal stem cells (BioXcellerator) in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by BioXcellerator. Started Jan 2020; status: terminated.
02
Drugs
Wharton's jelly-derived mesenchymal stem cells (BioXcellerator)
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04390152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390152.